Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population

Xiaohong Pu(Nanjing Drum Tower Hospital), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region), Jiong Shi(Nanjing Drum Tower Hospital), Xiangshan Fan(Anhui Medical University), Hongyan Wu(Hong Kong Baptist University), Liang Mao(Nanjing Drum Tower Hospital), Qing Ye(Children's Hospital of Zhejiang University), Jun Chen(Fourth People's Hospital of Taiyuan), Jun Yang(China Three Gorges University), Yudong Qiu(Nanjing Drum Tower Hospital), Xiwei Ding(Nanjing Drum Tower Hospital)
Human Pathology
March 4, 2018
10.1016/j.humpath.2017.12.028
Cited by 14

Related Papers

Food, nutrition, physical activity, and the prevention of cancer: a global perspective
|Choice Reviews Online|2008|5.4k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
|Cell Metabolism|2020|1.7k
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
|Clinical Gastroenterology and Hepatology|2021|708
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683